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Objectives: To investigate the mental health of rheumatic diseases patients and 
explore the effect of psychotherapy for the mental health status in rheumatism inpa-
tients. MethOds: 1. To compare the mental health status in rheumatism inpatients 
with normal by SCL-90 score. 2. 66 inpatients with rheumatism were recruited in 
the study and randomly divided into study group (n= 33) and control group (n= 33). 
The patients in the study group accepted psychotherapy and pharmacotherapy, and 
control group only accepted pharmacotherapy. 3. Six weeks later, the effect of psycho-
therapy to rheumatism inpatients were assessed by comparing the score of SCL-90 
between the two groups. Results: 1. The SCL-90 score significantly increased in 
rheumatism inpatients group compared with normal group: rheumatism inpatients 
group (152.8±35.9) and normal group (129.9±38.7), (P< 0.05). 2. Six weeks later, the SCL-
90 sore of study group was lower than that of control group. 3. The SCL-90 score sig-
nificantly reduced after psychological treatment. cOnclusiOns: The mental health 
status of rheumatism patients can not be ignored, because the patients have varying 
degrees of mental psychotic symptoms. The psychotherapy can improve the mental 
health status in rheumatism patients and can help the recovery of the patients.
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pRs1
the effeCtiveness and safety of febuxostat : an expeRienCe in 
MediCal CenteR in taiwan
Wang Y.S., Ng S.P., Kuo L.H., Chien S.Y.
Changhua Christian Hospital, Changhua City, Taiwan
Objectives: The aim of this study was to assess the effectiveness and safety of 
febuxostat for chronic gout. MethOds: We retrospectively review patients with 
diagnosis of gout (ICD-9 250) concomitant with febuxostat during Jun 2012 to Dec 
2013 in Changhua Christian Hospital. Patients with prescription of febuxostat less 
than 30 days were excluded. We collect the data of patient age, sex and analyzed the 
progression of renal function (eGFR) and uric acid. Prescribed Daily Dose (PDD) of 
febuxostat was calculated. Hospital-based spontaneous reporting systems databases 
were survey for the febuxostat adverse reaction reporting. Results: A total of 151 
patients were included with mean age 68.3±14.4 years. There were 40 female and 111 
male ( F:M ; 1:2.8).The average duration of prescription was 148.0±88.5 days. Prescribed 
Daily Dose (PDD) of febuxostat was 44mg. The uric acid was decrease from 9.1±1.9 to 
6.6±2.7mg/dL. The eGFR was increased from 33.5±23.5 to 34.9±25.1 ml/min/1.73m2. 
86.7% (131) of patients with eGFR < 60 ml/min/1.73m2 at the baseline. In subgroup 
analysis, 42 patients with the duration of prescription 31-90 days (average 55.8±15.6 
days ), 59 patients with 91-180 days(average 127.6±25.6 days), 50 patients with > 181 
days (average 249.6±68.77 days), the uric acid derement was 2.3±2.8 mg/dL, 2.6±2.9 
mg/dL and 2.8±2.1 mg/dL respectively. A total of 6 cases reported as mild adverse 
reaction, 4 cases reported as skin reaction. Other reactions reported was chills and 
insomnia.The incidence of ADR was 3.97%.(6/151). cOnclusiOns: Febuxostat is an 
effective urate-lowering agent. We found a trend that the longer Febuxostat use, the 
more uric acid decline. The safety of febuxostat was well tolerated since the adverse 
reaction reported was mild. The total 6 cases adverse reaction reported were occurred 
in eGFR < 60 ml/min/1.73m2. Therefore, we need to closed monitor adverse reaction 
in CKD patients.
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Objectives: Recent nested case-control studies have raised concerns of the risk for 
acute urinary retention (AUR) among patients receiving tiotropium, a long-acting 
inhaled anticholinergic. In this study, we examined the effect of inhaled anticho-
linergics on the occurrence of AUR using self-controlled methods, case-crossover 
and case-time-control designs, which adjust for all time-invariant confounders and 
reduce threat of control-selection bias. MethOds: Patients aged ≥ 45 years with 
chronic obstructive pulmonary disease (COPD) were included from the IMS LifeLink 
Health Plan Claims Databases. Cases with AUR in both inpatient and outpatient set-
tings during 2006-2009 were identified. In the case-time-control approach, ten con-
trols were randomly selected for each case after matching age, gender, geographic 
location, to control for the secular trend of medication use. Exposure to tiotropium, 
ipratropium, and medications with significant anticholinergic effects was deter-
mined in the 30-day period prior to the event and in a 30-day reference period which 
was 180 days prior. Multivariate conditional logistic regression was used to evaluate 
the association between anticholinergic exposure and AUR, with sensitivity analyses 
and subgroup analyses based on age, gender and related comorbidities. Results: A 
total of 6,008 cases and 60,080 controls were identified. The mean age was 74 years 
and ~78% were male. In the case-crossover analysis, adjusted odds ratio (OR) of AUR 
was 1.34 (95%CI 1.13-1.60) for tiotropium and 1.19 (1.00-1.41) for ipratropium. In the 
case-time-control analysis, the risk of AUR OR was 1.24 (1.03-1.50) for tiotropium and 
1.26 (1.05-1.51) for ipratropium. The AUR risk related to tiotropium and ipratropium 
was similar among patients aged > 75 years, males, and those with benign prostate 
hyperplasia, prostate cancer, and diabetes. cOnclusiOns: Our results support cur-
rent evidence that use of inhaled anticholinergics is associated with higher risk for 
AUR (odds increased by 20-35%) in COPD patients. Providers should be aware of the 
potential risk for AUR when making treatment decisions.
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and humanistic) requirements to support reimbursement and prescription of bio-
similar drugs in three Asian markets (Japan, South Korea and China). MethOds: 
We conducted secondary research to review the macroeconomic factors impact-
ing biosimilar entry (regulatory policy, intellectual property protection etc.) Payer/ 
physician guidance and positions on biosimilar use across markets and diseases 
were also reviewed. Following this, primary research was conducted with a mix of 
payers and physician stakeholders to understand: 1. The therapy areas that payers/
physicians consider most attractive for biosimilars; 2. Payer/physician value drivers 
and evidence requirements (bioequivalence, comparative data etc.) across therapy 
areas that would support public reimbursement and prescription. 3. Expectations 
around price differentials vs. branded biologics and the implications these 
differentials have on access and utilization of biosimilars. Results: Evidence 
requirements vary by market, with Japan and S.Korea being fairly consistent while 
China having lower thresholds. Evidence requirements also tend to vary by therapy 
area and complexity of the biologic. Overall, efficacy/ safety data and price are key 
value drivers for biosimilar reimbursement and uptake. In the absence of com-
parative data vs. the branded biologic, concerns around safety/efficacy may impact 
uptake but the promise of significant budget savings supports positive reimburse-
ment/ access decisions. cOnclusiOns: The access environments for biosimilars in 
the developed markets of Japan and S.Korea can be expected to be similar to other 
developed markets across the world. However, China is likely to be more favourable 
than the developed markets when it comes to access and uptake of biosimilars.
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Objectives: Historically, there has been a delay between the marketing approval of 
drugs in Western countries and other markets worldwide. However, the pharmaceuti-
cal market in Asia is rapidly expanding (a projected increase in global market share of 
7% from 2000–2016). The objective of this analysis was to investigate patterns of drug 
approvals in Western and Asian countries. MethOds: National English-language 
drug regulatory authority websites were searched for drug approval dates in key 
Western (United States and European Union) and Asian countries (Japan, Hong Kong, 
Indonesia and Singapore) in type 2 diabetes mellitus (T2DM) and rheumatoid arthritis 
(RA). For drugs with ≥ 1 approval in each region, we analysed how the delay in average 
approval date between the West and Asia changed over time. Results: At least 1 
West and 1 Asian approval was recorded for 21 drugs (T2DM n= 12, RA n= 9), out of the 
31 included. The delay between approval in the West and Asia was found to decrease 
between 2000 and 2014 in both T2DM and RA, and there was an overall strong negative 
correlation between the date of first approval and the delay (p< 0.0001; Spearman Rank 
correlation). Despite the delay for RA drugs (mainly biologics) being over double that 
of the T2DM (all small molecules) in 2000 (8.6 vs 3.6 years), by 2009 the delay for drugs 
in both indications was less than 2 years, due to a greater rate of decrease in delay for 
RA. cOnclusiOns: Whilst the current analysis has limitations, it is clear that the 
delay in date of approval of T2DM and RA drugs in Western and APAC countries has 
decreased dramatically over the past decade. This may have an impact on the future 
marketing strategies of pharmaceutical companies. Further analysis would be needed 
to ascertain if this same trend is observed in other emerging markets.
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Objectives: Every year, osteoporosis accounts for two million fragility fractures 
leading to disability, decreased quality of life and increased health care cost. Health 
literacy poses a challenge in delivering effective health care services. Impact of 
health literacy on health care utilization in the osteoporotic patients is unknown. 
We describe(1) health care utilization for osteoporosis patients in the USA(2) their pre-
scription drug expenses, and(3) examine any effects that health literacy may have on 
the above factors. MethOds: This cross-sectional analysis used Medical Expenditure 
Panel Survey(MEPS) survey data from 2005 - 2008 and patients were identified using 
ICD-9 codes (733.xx) for osteoporosis. Patients’ health literacy levels(HLL) were 
determined by using the health literacy scores(HLS), rated using the 2003 National 
Assessment of Adult Literacy to levels from basic or below basic(BBHLL< 226) to above 
basic (ABHLL≥ 226) (range 0–500). The outcome variables were visits and costs as a 
function of HLL adjusted for other covariates. Adjusted logistic regression analyses 
determined factors that might influence HLL in osteoporotic patients. Results: 
Majority of the total of 915 (20,486,934 weighted) individuals (mean age, 67.4; SD±11.7) 
were women (92%), Caucasians (91%) and on bisphosphonates (78%). The estimated 
national mean of HLS was 220.3(SD±27.5). Average annual visits and visits expenditure 
were 13.9 and $1,587 respectively. Individuals with ABHLL incurred less annual visits 
(13.4 vs 14.3) but paid more per visit ($130vs.$103) compared to those with BBHLL. 
Self-perceived health status( SPHS) was rated 2.35 times greater by ABHLL than those 
with BBHLL (OR:2.352,CI:1.43,-3.87). Patients with polypharmacy(> 4 drugs) were 1.87 
times less likely to have ABHLL(P< 0.0001) than those with BBHLL. cOnclusiOns: 
Osteoporosis patients with ABHLL incurred less annual visits but paid more per visit. 
While increasing HLL may not decrease visits or expenditure per visit, it may decrease 
drug expenses, polypharmacy and improve SPHS, all associated with better health 
care outcomes.
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